Ariad Pharma (ARIA) Misses Q4 EPS, Revenue Expectations
Get Alerts ARIA Hot Sheet
Join SI Premium – FREE
Ariad Pharma (NASDAQ: ARIA) reported Q4 EPS of ($0.38), $0.19 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $78 thousand versus the consensus estimate of $940 thousand.
For earnings history and earnings-related data on Ariad Pharma (ARIA) click here.
For earnings history and earnings-related data on Ariad Pharma (ARIA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Okta upgraded as AI security opportunity boosts outlook
- Why Michael Burry says Berkshire is no longer attractive under Abel
- Adamas Trust prices $90M senior notes offering at 9.600%
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share